Hot Investor Mandate 2: Corporate VC Invests In B2B Healthcare IT and Approved Medical Devices

The corporate venture capital arm of a corporation has $6B in AUM and provides a variety of venture financing solutions in a mix of debt and equity structures to growth-stage companies in the technology and life science space. Initial investments typically range from $5M-$20M, with additional capital reserved for follow-on investments. The firm does not make strategic investments, but rather is focused on returns and makes all investments directly from its balance sheet; therefore, there are no time constraints for returns. The firm aims to do between $150M-$200M in deals per year. Board seats are not typically required; however, board observation rights may be required depending on the deal.

In the life science space, the firm is most interested in healthcare IT and medical devices (diagnostic or therapeutic). The firm will consider earlier-stage health IT companies without any revenue, but medical device companies must have FDA approval and would be preferred if they were generating some revenue. The firm is most interested in health IT companies with a B2B aspect, whether that be clinical or business systems, and will look at consumer-facing healthcare IT technologies on a secondary basis.

For the most part, the firm invests in North American companies, but will consider Asian companies secondarily. The firm requires that management teams have a quality track record that demonstrates their ability to execute.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: New Venture Fund Seeks Therapeutics, Medtech and Advanced Life Science Tools Worldwide

A California-based firm is investing from a new fund that closed in early 2016.  The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment.  The firm invests 90% of its capital in the USA, Japan and Israel, with the remaining 10% open to global opportunities.

The firm invests in advanced therapeutics, healthcare IT, novel devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field.  Technologies of interest to the firm include 3D tissue scaffolds, organs-on-a-chip, second generation diagnostics, and single cell tracking.  The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer.  The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Global Big Pharma Seeks Assets in Oncology, Neurodegenerative Diseases, and Immunology

A US-based large pharmaceutical firm forms partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The firm looks globally for opportunities.

The firm focuses on therapeutic assets in oncology (including immuno-oncology), immunology, and neurodegenerative diseases. The firm is also interested in fibrotic diseases of the liver (such as HBV). The firm is open to biologic, small molecule and cell therapy opportunities. The firm will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Top Takeaways for Pitching from the WIB, JLABS, and J&J Innovation Lobster Pot

By Christine A. Wu, Research Analyst, LSN

chrsitine

The Lobster Pot was boiling last Wednesday at the Women in Bio and Johnson & Johnson Innovation Shark Tank-style pitch event in Cambridge, MA. Organized by the LSN team, eight female life science CEOs gave 6-minute pitches proceeded by short sessions of feedback from five female investors.

So how hot did the “chef” investors boil these “lobster” CEOs? Below are common critiques to fundraising entrepreneurs – be sure to take these into account for your next presentation.DSC03757

Address your Audience

Keep in mind who your audience is and tailor your message appropriately. Take into account their background and expertise – what do they already know? What areas require more explanation? Does the audience already know your target market? Will the audience understand you? Often times, the entrepreneur will take a longer time to explain the overall market when the investor is already familiar and instead wants other questions to be answered (i.e. the science and data, management team, revenue generation, etc.). Especially if your audience has a scientific background, be sure to include your mechanism of action if developing a therapeutic product. Knowing your audience will give you a better idea of what can be briefly addressed and where to delve deeper.

Address the Patient Impact

Take a step back from your clinical evidence and remember to give a broad overview of what this all means for the patient population. What are you trying to change? Think about compliance, symptom monitoring, reimbursement, your endpoint. How are the patients going to use your technology and how will it change their everyday lives?

Explain how to get to the Provider(s)

It’s important for investors to know how the technology gets into an actionable set of hands. Look past the fundraising and commercialization process and answer how the technology will be ultimately distributed, analyzed, and utilized. If you are developing a direct to consumer technology, make sure to mention the pricing and distribution model along with regulatory involvement. Furthermore, you need to address how to convince physicians to give up their current gold standards of care, especially if you’re in an established disease market. Additionally, if developing a diagnostic, be sure to address how you control false negatives – how comfortable are you and how comfortable will the physician be with its diagnosis/validation?

Include your Development Timeline

You should summarize your entire development timeline in one easy slide. This includes the reimbursement pathway; the FDA regulatory process and approval; the clinical trials and commercialization strategy; and where you currently lie.

Include how much you are currently fundraising, what milestone it will get you to, and the future inflection points. If your technology is currently on-the-market, include its revenue generation.

Keep your Slides Simple

Slides should be easy on the eyes. A common critique was that slides had too many words, not enough visuals, and that slides can often times be consolidated. Can the audience look at your slide and know your point in just a few seconds? It was also advised to know your pre-money valuation, but not to include in your slides, as it would likely be as high as you will get and more difficult to negotiate down the road.

Address your Competitors & Strategic Partners

You must address who your competitors are upfront. Demonstrate how the technology compares to anything else being developed and on the market. On the other end of the spectrum, include who might be strategic partners. These will demonstrate your knowledge of your market segment in its entirety.

Show your Management Team & Advisers

Be sure to acknowledge your team and the experience behind it. Who is supporting you and who are your advisers behind the scenes? Show off your team as thoroughly as you can.

Practice your Pitch

Deliver your overall vision at the start – be sure to nail down the introduction. You should start with the problem; how it is treated today; what’s wrong with the current therapy; and how you are addressing it. If under a time crunch, practice your pace. You should be clear and direct. Let your passion come through the presentation and show ownership in its delivery.

DSC03765

RESI@TMCx Panel Announcement: Diagnostic Investors

By Cole Bunn, Research Analyst, LSN

cole-wp

The diagnostics space encompasses a very wide range of technologies targeting indications across the board, and is arguably the most difficult sector, under the life science umbrella, to successfully navigate. Not only do these entrepreneurs have to first identify the correct capital providers and strategic partners to make their technologies a commercial reality, like everyone else, but piquing the interests of those entities may be considerably more difficult. Oftentimes, clearly articulating the value proposition of your diagnostic product/service is a little trickier than that of a more traditional therapeutic or medical device, and the go-to-market strategy for these technologies will usually be more highly scrutinized.

Moderated by John Walter, CEO & President, Alliance for Cancer Gene Therapy Foundation, this session will feature:

Given the complex strategic landscape diagnostics often face, along with the importance of the having the correct strategy in place, the value of guidance and feedback from experienced diagnostic investors can’t be overstated. This diverse set of panelists, representing a variety of different funds and organizations, will give the audience firsthand perspectives to help position their companies for success.

Registering for the RESI Conference will give you the opportunity to listen to this panel live, connect with relevant investors and network with like-minded entrepreneurs.

RESI@TMCx Panel: Medical Device Investors Share Their Strategies

By Lucy Parkinson, Director of Research, LSN

Medtech innovation is one of the focuses of Texas Medical Center’s innovation programs, with TMCx focusing its startup acceleration program on medical devices and healthcare IT. RESI@TMCx will provide a venue for investors to meet with innovative medical device startups from Texas and beyond, and this panel session will explore what it takes to get a new device product funded and commercialized.

Moderated by Angela Shah, Editor, Xconomy, the panelists are:

The panelists will share their experience and insight on the medical device sector, including what areas of medical technology are of peak interest right now, what factors they examine when performing diligence on a medical device company, and what opportunities they see for the future of device innovation. If you’d like to hear from these experienced investors and from our expert moderator, you can register for RESI now.

Hot Investor Mandate 1: Private Wealth Fund Seeks Healthcare IT & Mobile Health Technologies

A New York based venture investment firm with a single LP looks to make growth-stage investments in the form of preferred equity, ranging from $1M-$5M initially, with additional capital reserved for follow-on financings, typically up to $10M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 2-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.

The firm makes about one-half of its investments in healthcare, and is open to any healthcare companies that do not require FDA approval for their product/service. However, the firm focuses on B2B-oriented healthcare services and healthcare IT solutions.

The firm typically looks for growing companies with a run rate of $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and will work with first-time entrepreneurs. The firm looks to take a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com